Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
- Conditions
- Lung Cancer, Nonsmall Cell
- Interventions
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 310
- Registration Number
- NCT04028778
- Locations
- 🇨🇳
Cancer Center of Sun Yat-Sen University (CCSU), Guangzhou, Guangdong, China
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 247
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Beta Pharma Shanghai
- Target Recruit Count
- 369
- Registration Number
- NCT03866499
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Linyi Cancer Hospital, Linyi, Shandong, China
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
- Target Recruit Count
- 406
- Registration Number
- NCT03856697
- Locations
- 🇨🇳
Guangdong Provicial People's Hospital, Guangzhou, Guangdong, China
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 429
- Registration Number
- NCT03849768
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
- Conditions
- Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
- Interventions
- Drug: Placebo AST2818 80mg//40 mg
- First Posted Date
- 2018-12-27
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT03787992
- Locations
- 🇨🇳
cancer hospital Chinese academy of medical sciences, Beijing, China
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 66
- Registration Number
- NCT03766490
- Locations
- 🇨🇳
The First Affiliated hospital of soochow university, Suzhou, Jangsu, China
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 158
- Registration Number
- NCT03758287
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT03656393
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients with Central Nervous System (CNS) Metastases
- Conditions
- EGFR Gene MutationNon-small Cell Lung CancerBrain Metastases
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
- Target Recruit Count
- 492
- Registration Number
- NCT03653546
- Locations
- 🇨🇳
China site, Tianjin, China
🇨🇳China site 0123, Jinan, Shandong, China
🇰🇷Korea Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.